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Sammendrag
Androgene anabole steroider er i idrettssammenheng et mye brukt ulovlig middel
for a˚ øke prestasjonsevnen. For a˚ avdekke misbruk, doping, er en urinprøve veleg-
net. Identifisering av steroidet og/eller dets metabolitter forutsetter tilgjengelighet
av etablerte referanser for sammenligning. Bruk av utskillelsesforsøk for kart-
leggelse og opparbeidelse av relevante referanse metabolitter, er ressurskrevende
og etisk omdiskutert. Bruk av mikrosomer er derfor et aktuelt alternativ. Ma˚let
med denne oppgaven var a˚ syntetisere og identifisere metabolitter fra kjente og
sjeldne anabole androgene steroider, ved bruk av humane levermikrosomer. Lev-
eren er et viktig organ for steroid metabolismen. Inkubasjon av anabole androgene
steroider med humane levermikrosomer, utgjorde en in vitro simulering av lever-
metabolismen. En bekreftelsesmetode for metabolitter bestod i gasskromatografi
tandem massespektrometri i fullstendig søk, MRM-modus, eller begge kombin-
ert. 6β-hydroksymetandienon, epimetandienon og 17,17-dimetyl metandienon ble
dannet under inkubasjon av metandienon. 17β-hydroksymetyl metandienon ble
produsert fra 17,17-dimetyl metabolitten. Henholdsvis tre og e´n metabolitt(er)
ble funnet for ”designer steroidene” metylnortestosteron og madol. Metabolittene
viste store variasjoner i optimal inkubasjonstid og enzymatiske forutsetninger for
dannelse.
Abstract
Anabolic androgenic steroids are substances frequently misused to improve phys-
ical performance in sports. To reveal substances misused as doping, athlete urine
samples are collected and tested. To identify the steroid and/or its metabolites
in urine, reference compounds must exist for comparison. The time-consuming
and ethical concerns about in vivo excretion studies for the examination of these
compounds, make the use of liver fragment microsomes an attractive alternative.
The aim of this thesis was to synthesize and identify metabolites from known and
rare anabolic androgenic steroids, by the use of human liver microsomes. Liver
is an important organ in steroid metabolism. By incubating AAS with human
liver microsomes and co factors, an in vitro simulation of the liver metabolism was
carried out. A confirmation of metabolites was performed by gas chromatography
tandem mass spectrometry in full scan, MRM mode, or both. 6β-hydroxymethyl
metandienon, epimetandienon and 17,17-dimethylmetandienon were successfully
synthesized from metandienon, and the 17β-hydroxymetandienon was produced
from the 17,17-dimethyl metabolite. Respectively three and one metabolite(s)
were found for the ”designer steroids” methylnortestosteron and madol. Metabo-
lite variations were observed regarding the optimal time of incubation, and enzy-
matic requirements of formation.
Keywords: Metandienon, methylnortestosterone, madol, microsomes, dop-
ing, GC-MS/MS
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Chapter 1
Introduction
The practice of enhancing sport performance with supplements, might be as old as
sporting itself. In ancient Greece, during the 4th century B.C., Aristotle described
how athletes consumed special diets, like testes from strong animals, preferably
to improve their performance9. Doping in modern time is known from late 19th
century, by the use of e.g. caffeine, cocaine or strychnine derived from plants
or animals35. The International Amateur Athletic Federation tried to prohibit
doping in 1928, but made no success as it was both demanding, and in many cases
impossible to control or confirm misuse of doping substances at that time51.
1.1 History of doping
Doping in sports is defined as the use of drugs to enhance performance of an
athlete8. It tampers with the spirit of fair play, and is considered cheating by
sports organizations. Several drugs of various kinds are considered as doping. The
most common, are androgenic anabolic steroids52.
Misuse of anabolic steroids in sports dates back to the nineteen fifties24. Testos-
terone was the first androgenic anabolic steroid (AAS) suspected to be abused,
succeeded by synthetic testosterone analogues. These became available when drug
companies met an increasing demand in connection with the discovery of their use-
fulness, in treating a wide range of endocrinological diseases35. As a consequence,
the medical committee of the International Olympic Committee (IOC), introduced
the first list of prohibited substances (”the code”) in 196853. AAS were placed
1
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in ”the code” in 197624. Compulsory tests followed in the succeeding winter- and
summer- Olympic Games. In 1999, the IOC convened the World Conference on
Doping in Sports, as a result of deviating apprehensions and rules in international
and national anti-doping organizations. The independent organization, the world
anti-doping agency (WADA), was founded, and is today responsible for control and
revise of prohibited substances and methods51. WADA presents ”the code” on a
yearly basis, which is the foundation of tests performed by accredited laboratories
for control and confirmation of doping.
1.2 Control and confirmation of anabolic steroids
In doping control analysis, body fluids from athletes are tested by WADA accred-
ited laboratories to reveal prohibited substances4.
Technology has improved the testing techniques25, focus and communication in
the work of doping control analysis. Test intervals and occurrence have improved
dramatically52, and a large number of substances and cover ups are today included
in the screening. AAS are the most widespread misused substance in today’s
doping52. Extensive research and control has therefore been put forward to ensure
”fair play” in athletic context.
To perform doping control analysis on anabolic steroids, athlete urine samples may
be collected at any time, and sent to accredited doping control laboratories for
analysis. Since the nineteen sixties, instrumental analytical tools have been used
for this purpose25. Identification and quantification of AAS can be performed by a
combination of chromatography and mass spectrometry42, a method explained in
section 2.7. Accredited laboratories must in most cases identify, but not quantify
prohibited substances26;4. Hence irrefutable detection of prohibited AAS or their
metabolic products need reliable confirmation. This is accomplished by the use
of certified reference compounds. Many AAS are completely metabolized in the
human body43. To identify and/or examine a steroid and its potential metabolites,
it is an increasing demand to both understanding and carrying out the steroid
metabolism42;29.
Furnishing of reference compounds has been approached in several ways, among
them, through chemical synthesis, and through in vivo excretion studies42. A
chemical synthesis of potential metabolites requires a well understood metabolism,
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and a known or suggested metabolite molecular structure. It provides pure com-
pounds, but has limited stereo specificity30. An issue possibly solved by isolation
and purification of metabolites from excretion studies, giving healthy volunteers
steroids40. The excreted metabolites from urine may prove as references to chemi-
cally synthesized compounds, or in direct comparison to urine samples in a doping
control analysis. Since many steroids produce known or unknown side effects,
both ethical and medical concerns are associated with exploring AAS and their
metabolites in the latter way29.
In recent years, alternative approaches to obtain reference metabolites have been
proposed. Zo¨llner et al.58 synthesized the 17β-hydroxymethyl metabolite of the
AAS metandienon by recombinant yeast strains. The strains of Schizosaccha-
romyces pombe were modified to express different human hepatic enzymes. This
method proved successful in synthesizing enough reference material for structure
characterization. Each yeast culture expressed different human enzymes, which
made it possible for only one enzyme to be examined at a time.
Kuuranne et al.30;29 examined an alternative approach, to obtain reference metabo-
lites by the use of human liver microsomes. Several metabolites of AAS were ex-
amined for their in vivo- in vitro correlation with microsomes as an in vitro source
of metabolizing enzymes. This technique was recently approved by WADA as a
method to derive reference compounds of steroid metabolites1, but has never been
performed in Norwegian anti-doping research.
The aim of this thesis was to explore the use of microsomes as a technique to syn-
thesize metabolites from an AAS. Metandienon was chosen as the model AAS, as
its metabolism is well known, while madol and methylnandrolone were substances
with limited information regarding their metabolic pattern. An additional purpose
was to establish an analytical method to determine metabolites resulting from the
synthesis.
First, a brief review of some basic theory is given. Section 2.2 provides a frame-
work to understand anabolic steroids and its metabolites in general. Section 2.4
is devoted to the general concepts behind the liver metabolism, with an addi-
tional subsection on microsomes. Sample processing in doping control analysis is
reviewed in section 2.6. The concepts behind gas chromatography tandem mass
spectrometry is outlined in section 2.7, with emphasis on method optimization by
multiple reaction monitoring transition and general steroid detection. Next, in
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chapter 3, establishing the method for detection, and assay of in vitro synthesis
of metabolites are presented. Results of establishing the detection-method, and
synthesized metabolites are presented and discussed in chapter 4. The conclusion
is given at the end, together with suggestions for future work.
Chapter 2
Theory
The theory given here, explains the chemical basis and therapeutic application
of use of anabolic steroids. This serve as a background for the understanding
of its usefulness, burden and complexity. All are important aspects to consider
in the fight against doping in sports. Both general characteristics of anabolic
androgenic steroids and some specific prohibited compounds are covered in this
chapter. As a framework for the experimental design, sample preparation in doping
control analysis and analysis by gas chromatography tandem mass spectrometry
is outlined too.
2.1 Steroids
Steroids are a large group of chemical components classified collectively by their
structural likeness. The structural core of a steroid consists of four rings of car-
bon8, as shown in figure 2.1. Three rings (A, B and C) with six carbon atoms,
and one (D) with five.
Double bonds and ring substituents are crucial for the steroid interaction with re-
ceptors associated with the cellular membrane, where it may function as a ligand16.
Steroids are important ”biological regulators”, often with powerful physiologic ef-
fect when administered to living organisms46. Among these are the male and fe-
male sex hormones, adrenocortical hormones, and D-vitamins. The sex hormones
are further classified in three major groups: estrogens (female sex hormones),
androgens (the male sex hormones) and progestines (pregnancy hormones)46.
5
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Figure 2.1: The steroid core molecular structure. The characteristic carbon
rings: A, B, C and D are labeled.
2.2 Anabolic androgenic steroids
Anabolic and androgenic are terms describing effects of some steroid hormones.
Anabolic actions refer to affected protein metabolism through increased protein
synthesis and/or inhibited protein breakdown23. Androgenic, refer to development
of male characteristics, such as hair growth and deepened voice46. In the WADA
prohibited list, the steroid hormones are divided into two classes: endogenous and
exogenous steroids27.
Some androgenic anabolic steroids (AAS) are natural internally produced, and
function as hormone signals in the human body17. These are termed endogenous
AAS (endogens), as the word endogenous stands for internal origin8. Endogens
are needed for normal cell function. Two endogens are testosterone, shown in
figure 2.2, and dihydrotestosterone4. Endogens are usually well regulated by the
human signal system, unless pathologically influenced, or subjected to compounds
that compete for the same receptors.
Figure 2.2: The molecular structure of testosterone, labeled with carbon- ring
names and numbers.
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The history of anabolic steroids began with the discovery and synthesis of testos-
terone, the male sex hormone. In the mid 19th century, Arnold Berthold were one
of the first scientists that acknowledged the testes influence on sexual and behav-
ioral characteristics. He suggested that the characteristics resulted from the testes
secreting a substance into the bloodstream17. Later, in 1889, Charles Edouard
Brown-Se´quard reported an increase in strength and mental abilities (!) as a re-
sult of self-injections of extracts derived from animal testicles. In the beginning
of the 20th century, two British scientists concluded that this substance (among
others) function as blood borne messengers, which they named hormones. They
argued that the hormones regulated many body functions far from the tissue of
origin17. The synthesis of testosterone was achieved and published in 1935, almost
simultaneously by Butenandt and Hanish, and Ruzicka and Wettstein.
2.2.1 Testosterone analogues
Exogenic AAS (exogens) are synthetic analogues of testosterone23. The discovery
of 17α-alkylated testosterone revolutionized the prospective of anabolic steroids.
17α-alkylation gave the potential of activity upon oral administration of steroids5.
Many exogenic compounds do exist for therapeutic purposes. A goal for the devel-
opment of therapeutic AAS has been to minimize the androgenic and maximize the
anabolic action28. Methylandrostenediol was the first steroid that showed a differ-
entiation in anabolic and androgenic action. Research on which modifications that
gave anabolic properties without the androgenic characteristics has succeeded49,
but also revealed that these effects are closely resembled. Testosterone and syn-
thetic testosterone derivatives are often termed as androgens. Androgens mediate
their action through biding to the androgen receptor (AR). The different struc-
tural features of steroids, such as β-connected hydroxy-group in the 17-position,
presence of C-4, -5 double bond, and 3-keto group in the A-ring, all influence the
androgenic and/or anabolic activity14. Today, still no steroid is solely anabolic.
When orally administered, testosterone is rapidly absorbed in the portal vein,
and is subjected to extensive metabolism (often with loss of effect) in the liver
(first-pass effect)41. Chemically modified testosterone can circumvent the first-
pass effect, providing an increased oral availability28. Even though exogens mainly
were develop for medical purposes, they are unfortunately also widely misused as
doping. The metabolic profile of the exogenous steroids show similarities with
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that of testosterone39, and is to a large extent altered at positions of functional
groups. A wide variety of metabolites can be found in human urine subsequent to
the administration of synthetic AAS.
2.2.2 Metandienon
Metandienon (MD, 17β-hydroxy-17α-methylandrosta-1,4-dien-3-one) is an exo-
genic AAS. MD possesses a range of different names, among them dianabol. The
chemical structure in figure 2.3 manifests that MD is a 17α-methylated testos-
terone (methyltestosterone) with an introduced double bond between the first and
second C-atom39.
Figure 2.3: The molecular structure of metandienon.
MD has anabolic effects, but exhibit less androgenic effects than its endogenic
precursor5. This might be due to the change in structure, or the potentially
reduced testosterone level when administered in high dosages23.
MD was for the first time synthesized in 1958 and further permitted for use in
pediatrics, due to its low androgenic activity5. Unfortunately it was misused as
doping already in the world championship for weightlifters in 196235, and became
popular as a doping preparation. Today, MD is the most misused AAS reported by
WADA accredited laboratories52. MD and other 17α-alkylated steroids do often
affect the liver function, the heart, and can result in changes in human behavior5.
Chapter 2. Theory 9
2.3 ”Designer steroids”
”Designer steroids” are steroids produced to closely resemble existing AAS, but
with sufficient structural differences to avoid detection by WADA accredited lab-
oratories27. Some ”designer steroids” were partly examined in trials decades ago,
but never commercially marketed, nor used in pediatrics. Only limited or no
available data exists regarding their toxicological and pharmacological effects in
humans4;27. The first revealed ”designer steroid” was norbolethone, a steroid
tested decades ago for medical purposes, but never launched as a commercial
product6. After discovering a second ”designer steroid”, the WADA science di-
rector expressed a concern regarding the progress of steroid abuse, with the sole
purpose of ”designer steroids” being used as doping agents50. ”New” ”designer
steroids” are not registered on WADA list of prohibited substances, but are cov-
ered through the implemented phrase: ”and related compounds”54. Since their
structure differs from known steroids, ”designer steroids” are often not embedded
in the screening in regular doping analysis44, and are therefore more difficult and
often impossible to detect.
2.3.1 Methylnortestosterone
The exogenous AAS, methylnandrolone or methylnortestosterone (MeNT, 17β-
hydroxy-17α-methyl-5α-estr-4-ene-3-one), is a 3-keto-4-ene steroid, shown in figure
2.4. The distribution of MeNT as a potential pharmaceutical was closed decades
ago. It recently reappeared as a drug available through the Internet market7, and
is considered as a ”designer steroid”.
Figure 2.4: The molecular structure of methylnortestosterone
MeNT does most likely exert its action on AR through providing androgenic and
anabolic action. Speculations on the steroid activity follows the reasoning by
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Fragkaki et al.14. The structure of MeNT has similarities with that of MD and
nandrolone. Compared to testosterone, 17α-alkylation and 19-methyl removal (19-
nor steroids) favours anabolic activity. A 19-nor structure also reduces androgenic
activity. In that way, MeNT may very well be a potent anabolic inducer.
2.3.2 Madol
The exogenic AAS Madol (17α-methyl-5α-androst-2-en-17β-ol) (figure 2.5), also
known as desoxymethyltestosterone, is one of the first known designer steroids44.
The patent on Madol was awarded decades ago, but for unknown reasons, never
launched as a pharmaceutical10. In early 2005, the WADA accredited UCLA
Olympic Analytical Laboratory (USA) and Montreal laboratories (Canada), si-
multaneously, and independently revealed their discovery of madol from an oily
substance44;50. They discovered this substance as a result of intensive and collab-
orative investigation nationally. The madol mixture showed mainly madol, but
also traces of its 3-ene isomer. Impurity in a drug preparative is indicative of a
manufacture outside the professional pharmaceutical industry50.
Figure 2.5: The molecular structure of madol
Diel et al.10 used tests for biological activity in orchiectomised rats (i.e. had
their testes removed), to characterize the pharmacological profile of madol. They
concluded that madol is a powerful anabolic steroid, but they also addressed toxic
side effects, such as a hypertrophic heart. Madol is placed on WADA prohibited
list54, but has limited detectability in today’s screening. Several websites offer
madol as a performance enhancing ”supplement”.
It should be mentioned that additional side effects may result from the use of
madol. Even though Diel et al.10 characterized the pharmacological profile of
madol, they used pure madol in their experiments. As reported by WADA50,
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madol available on the Internet marked, is of a different purity grade and include
additional steroid compounds. This may result in a different metabolic outcome,
and an unknown metabolic profile.
2.4 Steroid metabolism
Besides the processing and distribution of nutrients36, the liver provides metabolism
of exogenous compounds to prevent potential hazardous effects57. The liver is the
first organ to encounter ingested compounds as venous blood flows directly from
the stomach and intestine, through the portal vein, to the liver55. The liver is
rich in metabolizing enzymes that can transform non polar AAS (orally admin-
istered) in two ways. These metabolic transformations are accomplished by a
limited number of enzymes with a broad substrate specificity.
2.4.1 Phase I reactions
Phase I reactions involve hydroxylation, epimerization, oxidation and reduction55.
These enzymatically catalyzed reactions alter AAS functional groups. Usually this
increases the polarity and/or makes AAS more accessible to phase II metaboliz-
ing enzymes55. The primarily superfamily of phase I enzymes are cytocrome P450
(CYPs)57, which hold catalytic versatility55. CYP enzymes catalyze the monooxy-
genation of a compound while reducing the other oxygen to water. Reducing
equivalents derive from electrons from nicotinamide adenine dinucleotide phos-
phate (NADPH), transferred to CYP via the flavoprotein NADPH-cytochrome
P450 reductase. Both CYP450 and the NADPH reductase are embedded in the
phospholipid bilayer of endoplasmic reticulum (ER), which facilitates their inter-
action55. Epimer formation is an interesting reaction and object of discussion12;43.
The mechanism is considered to be a sulphate conjugation, followed by nucle-
ophilic attack by water on the labile conjugate. This do further produce a dehy-
dration product, which in the case of methyl steroids result in a 17,17-dimethyl-
18-norandrost-13-ene structure43.
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2.4.2 Phase II reactions
Phase II reactions include glucuronidation, sulphation, acetylation and conjuga-
tion with glutathione55. These usually increase the hydrophilisity and the excre-
tion of a compound57. The main phase II reactions for AAS are glucuronidation
and sulphation29. These reactions play an important role in conjugation and
elimination of compounds with hydroxyl functional groups57. Glucuronidation is
enzymatically catalyzed by UDP-glucuronosyltransferases (UGTs). The reaction
also requires the cofactor Uridine-5’-diphospho-β-D-glucuronic acid (UDPGA)55.
Sulphation is catalyzed by sulphotransferases (SULTs). SULTs involved in steroid
metabolism are soluble and cytosolic47, and require 3’-Phosphoadenosine-5’-phos-
phosulphate (PAPS) as a cofactor in the sulphonate transfer55. SULTs generally
produce a highly water soluble ester of sulphuric acid (O-sulphonation), which
inactivate the steroid ability to bind to the receptor47. SULT2A1 (a SULT sub-
family) sulphonate a variety of substrates, including the 17β-hydroxyl group typ-
ical for steroids. Kuuranne et al.29 suggested that a low cellular concentration of
PAPS may limit the sulphation conjugation of steroids, a statement supported by
Watkins et al.55. The SULT activity has also been reported slow. Apart from that,
little or no investigation has been performed to examine the influence of PAPS
availability on sulphoconjugation reactions47.
2.4.3 Microsomes
Microsome originates from the Greek words micros (small) and soma (body). Mi-
crosomes are small cytoplasmic fractions, preferably with pieces from endoplasmic
reticulum (ER), isolated with or without ribosomes3. Human liver microsome-
preparations may prove useful in exploring ER, and when studying the liver-
metabolism of foreign compounds. Micorosom-preparations can be divided in two
categories: liver microsomal membranes (HLM) that contain numerous CYP and
UGT enzymes, and microsomal cytosolic components (S9 fraction), were SULTs
are present2. The level of enzymatic activity vary among humans due to envi-
ronmental or/and genetic factors55. To avoid these variations, companies provide
microsome-preparations from liver tissue from multiple donors (>100).
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2.5 Metabolites
Several studies have examined AAS with emphasis on their metabolic pattern11;41;34;37.
Based on such studies, Fragkaki et al.14 did a principal component analysis (PCA)
that pictured possible metabolites and alterations in the parent molecule. This
provides a powerful tool capable of foreseeing metabolites for detection of prohib-
ited compounds. The next three sections picture known and suggested metabolites
concerning the three AASs mentioned.
2.5.1 Metandienon metabolites
MD metabolites emerge in phase I and II reactions during MD metabolism in
the liver. Several metabolites are well described in literature33;42;58;37, and many
are today embedded in regular doping control analysis. An assortment of MD
metabolites are shown in table 2.1 and figure 2.6.
Table 2.1: Suggested metabolites for MD, according to estimates by Frakaki
et al.14.
Metabolic action Reported
C-4,5 double bond reduction to 5β-H isomer Yes
17-epimerization Yes
18-nor-17,17-dimethyl-13(14)-ene product Yes
18-nor-17α-methyl,17β-hydroxymethyl,13(14)-ene product Yes
3-keto reduction to 3α-OH isomer Yes
C-1,2 double bond reduction Yes
6α/β-hydroxylation Yes
16α/β-hydroxylation No
Double bonds at cites out of ring A reduction No
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Figure 2.6: MD [1] with metabolites; the 17,17-dimethyl metabolite [2], the
17β-hydroxymethyl metabolite [3], EpiMD [4], 6β-hydroxyMD [5], epimetendiol
[6], and the joint (with methyltestosterone) metabolite 5β-THMT [7]. The
arrows are only assumed pathways, as the metabolic pathway is yet not fully
understood.
The metabolic pathways and responsible enzymes in MD metabolism are well,
but not completely understood. 6β hydroxylation (B-ring metabolite) is the main
route for steroids of 17β-hydroxy-17α-methyl structure39. Several researchers have
synthesized 6β-hydroxy MD and detected it in urine after in vivo excretion stud-
ies5;40;11.
The 17-epimerization was debated in late 1980s, and partially solved by Edlund
et al.12, who claimed that this was a non-enzymatic reaction, resulting from nu-
cleophilic attach of the 17-sulphonate conjugate. He further argued that the labile
17-sulphonate probably also undergo dehydration that cause rearrangement of the
13-methyl group, yielding a 17,17 dimethyl metabolite depicted in figure 2.7.
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Figure 2.7: The rearrangement of metandienon to the 17,17-dimethyl metabo-
lite. The rearrangement is assumed to comprise a sulphoconjugated intermedi-
ate.
Parr et al.37 reported a regio- and stereo- specific hydroxylation of the 17,17-
dimethyl metabolite by the enzymes CYP3A4 and CYP21. A reaction that yields
the 17β-hydroxymethyl metabolite, as shown in figure 2.8.
Figure 2.8: The enzymatic hydroxylation of the 17,17-dimethyl metabolite to
the 17β-hydroxymethyl metabolite by CYP enzymes.
Metabolites from MD and their time of elimination, show inter individual varia-
tion, and depend on the metabolite in question41. Methods or compounds that
prolong the detection window of MD and other AAS are of great interest in the
field of anti-doping research. The 17β-hydroxymethyl metabolite was identified as
such a long term MD metabolite when it showed to be traceable in urine 19 days
post administration58.
2.5.2 Methylnortestosterone metabolites
In accordance to Fragkaki et al.16, no metabolite originating from MeNT has
been discovered. Anyhow, their statistical approach (PCA) suggests that several
metabolites may result from MeNT. Several metabolites were proposed in the
PCA, as summarized in table 2.2.
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Table 2.2: Suggested and/or possible metabolites for MeNT, according to the
PCA by Fragkaki et al.14.
Metabolic action Reported
C-4,5 double bound reduction to 5α, 5β-H isomers No
17-epimerization No
18-nor-17,17-dimethyl-13(14)-ene product No
18-nor-17α-methyl,17β-hydroxymethyl,13(14)-ene product No
3-keto reduction to 3α-, 3β-OH isomers No
6α/β-hydroxylation No
16α/β-hydroxylation No
Hydroxyl/keto groups at various sites oxidation/reduction No
to the corresponding keto/hydroxyl groups
Double bond(s) at sites of ring A reduction No
2.5.3 Madol metabolites
Somewhat more information exists on madol metabolites. According to Fragkaki
et al.14 PCA study, many metabolites are possible for madol as well (table 2.3).
The first attempt to generate madol metabolites was performed through a ba-
boon excretion study and human liver microsomes, but no clear metabolites were
found44.
Table 2.3: Suggested and/or possible metabolites for madol, according to
estimates by Fragkaki et al.14. *A combination of 2 and 3 hydroxylation, a
2,3,17-triol, has been reported by Gauthier et al.18. **Reported without con-
firmatory synthesis, and as combinations of the metabolic actions.
Metabolic action Reported
2-hydroxylation Yes*
17-epimerization Yes**
18-nor-17,17-dimethyl-13(14)-ene product Yes
18-nor-17α-methyl,17β-hydroxymethyl,13(14)-ene product No
3-hydroxylation Yes*and**
6α/β-hydroxylation Yes*
16α/β-hydroxylation yes
C-2,3 double bond reduction Yes
3-hydroxyl oxidation into 3-keto (from M3) Yes**
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Recently, Gauthier et al.18 discovered metabolites of madol by the use of human
fresh hepatocytes and human urine reference samples. Their proposed primary
metabolite of madol was 17α-methyl-2β,3α,17β-trihydroxy-5β-androstane. In ad-
dition were traces of minor metabolites seen, synthesized, and both a 3,4-diol, and
a sulphoconjugated metabolite were postulated.
Late 2012, Sobolevsky et al.45 identified several madol metabolites from excretion
urine samples. The detectability of observed metabolites varied up to two weeks
after administration. Main metabolites are depicted in figure 2.9.
Figure 2.9: The molecular structure of the main madol metabolites discovered
by Sobolevsky et al.45. [1] 17α-methyl-5α-androstan-2ξ,3α,16ξ,17β-tetrol, and
[2] 17α-methyl-5α-androstan-2β,3α,17β-triol.
2.6 Sample preparation for analysis
Several preparing steps are required when a urine sample arrives at an accredited
doping laboratory for analysis of AAS content. A low initial concentrations of
AAS requires extensive purification, and increased concentration in order to be
Chapter 2. Theory 18
suitable for detection. A procedure of stepwise preparation described by Bowers4,
and Scha¨nzer et al.43 is outlined next.
2.6.1 Enzymatic hydrolysis by β-glucuronidase
Many exogenic AAS are excreted as glucuronides. The enzyme β-glucuronidase
can be added to cleave molecular bonds to β-D-glucuronic acids. In doping control
analysis, enzymatic hydrolysis is the initial step for increasing the concentration,
and prepares samples for analysis4;32.
2.6.2 Extraction
Enzymatic hydrolysis provides non-polar metabolites that are transferable to an
organic solvent by extraction. Liquid-liquid extraction is a separation method
with two immiscible liquids, where the components in a mix are isolated by the
preferred solubility in one of the liquids. Isolation of the solute is then performed
by separation of the phases (e.g. a low temperature bath, where the aqueous
layer is frozen). Non-polar AAS are extractable in the non-polar solvent tert-
butylmethyleter (TBME), that allows extraction in a broad polarity range4. After
separation, increased concentration of the AAS is achieved by solvent evaporation.
2.6.3 Derivatization
AAS metabolites bear a wide range of different structural features, including hy-
droxyl and keto groups33. These groups are unfavorable in gas chromatogra-
phy analysis. To favor separation of metabolites by gas chromatography, and
further detection in the mass spectrometry analysis, a trimethylsilylation of the
hydroxyl and keto groups can be performed. In AAS processing, N-Methyl-N-
trimethylsilyltrifluoractetamid (MSTFA), ammonium iodide (NH4I) and ethanethiol
(EtSH) are common compounds in a mixture that initiates trimethylsilylation,
named derivatization4. Trimethylsilylation of MD by MSTFA, NH4I and EtSH is
shown in figure 2.10. Derivatization is today standard in steroid trace analysis in
doping controls48.
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Figure 2.10: Trimethylsilylation of hydroxyl and keton groups of MD
2.7 Instrumental
Several analytical methods that satisfy different requirements are available. In
the following sections, a brief explanation of a few analytical tools important in
doping control analysis is given.
2.7.1 Gas chromatography
Gas chromatography (GC) is an instrumental method that can separate com-
pounds in a mixture. The mixture of compounds is vaporized in a liner before
entering a column. The separation happens when compounds are distributed be-
tween a stationary phase and a mobile gas phase through the column19. The
compounds will differ in their interaction with the GC column material, resulting
in different distribution between the two phases. The GC column mainly sepa-
rate compounds (e.g. different AAS) by boiling point, and some on the basis of
polarity. This separation results in different retention time (RT). RT can also be
expressed as relative RT (RRT), for which it is relative to the RT of testosterone38.
For doping control analysis of small molecules in urine, GC is coupled with a
mass spectrometry (MS) to identify doping compounds in a sensitive and efficient
way25.
2.7.2 Mass spectrometry and tandem mass spectrometry
A mass spectrometry (MS) measures ion masses, as a mass to charge ratio (m/z ),
in a detector. In MS, an ion source provides a fragment pattern of a compound.
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The fragment pattern is distinct, and can serve as compound identification. Elec-
tron impact (EI) is a common and strong ionization technique, frequently used
in doping analysis48. EI applies energy, usually 70eV, to ionize and dissociate
compounds into fragments. Fragments are detected, and the MS software displays
a mass spectrum of ion-abundances against m/z. The dissociation pathway of a
compound (e.g. derivatized AAS) results in a distinct spectrum. This spectrum
provide the required data for determination of prohibited compounds in a dop-
ing control analysis48. When EI provides one fragmentation and ionization, the
displayed MS spectrum is known as a EI mass spectrum.
In the 1970s, chemical ionization (CI) and selected ion monitoring (SIM) were in-
troduced as additional analytical techniques25. CI is a more gentle ionization that
provides more abundant molecular ions. SIM is performed on a single quadrupole
that enables selection of specific ions in advance.
Tandem mass spectrometry (MS/MS) holds the capacity of a second fragmenta-
tion. This is provided by a collision cell known as collision induced dissociation
(CID). Selected ions (precursor ions) from a EI mass spectrum are introduced to
CID through a quadrupole. The CID provides a fragmentation pattern known as
a product ion mass spectrum. Specific product ions from the dissociation pathway
from the product ion mass spectrum may be selected through a second quadrupole.
The precursor and product ion transition represents a multiple reaction monitor-
ing (MRM) that provide superior specificity and sensitivity against background
noise31. Even an increased specificity is met through monitoring the ratio of the
identified MRM transitions within a compound. Amount of collision energy (CE)
applied in CID will determine the fragmentation level. The CE may be adjusted
in a method optimization to increase the sensitivity.
2.7.3 Gas chromatography tandem mass spectrometry
GC is today combined with MS or MS/MS to achieve high specificity and accuracy.
It is applied in screening of AAS, and is of great importance in science22.
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2.7.4 Dissociation pathways
A EI mass spectrum reveals a dissociation pattern, that may suite as compound
identification when compared to dissociation patterns of known references48. Frag-
ments refer to characteristic parts of the analyzed molecule.
General and specific characteristics in a full scan. The steroid structure
gives rise to distinct steroid ”fingerprint” fragments upon EI, shown as abundant
peaks in a mass spectrum. Fragment ions with m/z of 73 have little diagnostic
value as it derives from the loss of the [TMS]+ fragment, that are abundant in all
TMS-derivatives. D-ring fission between C13 and C17, and between C14 and C15,
give rise to the distinct pattern of m/z of 143. This is considered as a characteristic
fragment of 17α-alkylated synthetic steroids16
Loss of specific groups such as methyl or ethyl, is often a source of abundant
intensities in an AAS mass spectrum. A m/z of 103 indicates the dissociation into
the [TMSOCH2]
+, with [MW-103]+ also resulting as an abundant fragment. A
[MW-TMSOH-103]+ fragment may serve as a diagnostic characteristic16.
Chapter 3
Experimental
The experimental was divided into four parts: establishing a detection-method,
microsome incubations, microsome sample analysis, and urine sample analysis.
3.1 Establishing the detection-method
A detection-method was established by applying known reference standards of
steroids and metabolites, to GC-MS(/MS) in full- and product-scan mode. First,
chemicals and preparations of the steroids and MD metabolite reference standards
are described. Second, the focus is upon developing the method, by retention time
and MRM transitions, to detect in vitro synthesized metabolites.
During the pre-project for this thesis, a method for detection of MD and known
metabolites by GC-MS/MS were established. Here, this existing analytical method
was adjusted, by implementation of the 17,17-dimethyl metabolite. Detection of
proposed methylnandrolone and madol metabolites required a different angle of
methodology, due to the lack of known metabolites and not commercially available
reference standards.
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3.2 Reference solutions
The preparation of reference solutions was in accordance with that of the Nor-
wegian Doping Control Laboratory. Reference standards of MD, epiMD, 6β-
hydroxyMD, epimetendiol, 17,17-dimethyl metabolite were obtained from Aus-
tralien Government NMI. Reference standards of: the 17α-hydroxymetyl metabo-
lite, 5β-THMT, methylnortestosterone and madol had been obtained from: Ko¨ln,
NARL Steraloids Inc. and Chiron AS respectively.
Stock solutions (1 mg/ml) were pre-made, or made by dissolving pure compound
in methanol. Diluted stock solutions (50 µl, 10 ng/µl) of each component were
distributed in separate tubes.
50 µl methyltestosterone (internal standard (ISTD)) was added to each tube. One
tube was prepared containing a mix of all components and the ISTD.
All reference solutions in the tubes were evaporated under a stream of nitrogen
(N2) for 30 min. 100 µl MSTFA mix (described in section 2.6.3) was added to
each solution, and the solutions were derivatized on a heat block (50-55 ◦C) for
one hour. Derivatized solutions were transferred to vials with inserts, and applied
to GC-MS/MS for analysis.
3.3 Instrumental setup
The instrument setup was in accordance with regular doping control analysis of
AAS, with GC-MS/MS (Agilent) in split-less mode. The column was a SGE BPX5,
5 % phenyl column/95 % methyl polysilphenylene (15 m x 0.25 mm, film 0.22 µm,
5 % crosslink). Injector temperature was 280 ◦C. Initial column temperature was
160 ◦C, which was raised with 10 ◦C/min to 200 ◦C. Thereafter, the temperature
was increased with 2 ◦C/min to 220 ◦C. An increase by 20 ◦C/min gave an end
temperature of 310 ◦C. The flow was constant, and set to 2,4 ml/min. MSTFA
was injected directly, with no pre-column. The GC-MS single quadropole had a
HP ultra 1 (17 m x 0.20 mm, film 0.11 µm, 5 % crosslink) column in split mode
(ratio 10:1). Injector temperature was 280 ◦C. Initial column temperature was
180 ◦C, which was raised with 3.3 ◦C/min to 231 ◦C. An increase by 30 ◦C/min
gave an end temperature of 310 ◦C. The split flow was 6.0 ml/min. MSTFA was
injected directly, with no pre-column.
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An initial screening was performed on each reference compound and incubation
solutions of methylnandrolone and madol. It was performed in full scan mode,
with EI as the ionization technique. The detector area range in full scan mode
was set to m/z from 50 to 550. Known fragments (from literature and data library)
in the full scan were recognized, and respectively metabolite retention times were
found in the chromatogram.
For each steroid, and its metabolites, one or two precursor ions were selected
among the most abundant intensities in the EI mass spectrum.
A product ion scan was performed on these precursor ions. The upper range of the
product ion scan was set to m/z of 5 to 10 units above the precursor ions. From
the product ion mass spectrum of each precursor ion, one, two or three of the most
abundant product ions were selected. The pairs of precursor ions and associated
product ions were set as a MRM transitions. The MRM transition setup was
tested with the reference standard mix. The MRM transitions of MeNT and its
unpublished7 proposed metabolites were applied in addition to establishing the
detection-method from precursor and product ions of the incubated samples.
Several collision energies (CE) were applied to the MRM method, as an additional
optimization to achieve a more specific response. CE of 5, 10, 15, 20 and 25 V
were applied as trial CE for every MRM transition of MD and metabolites. CE of
MeNT was set as recommended by Chundela and Große7.
The CE that provided the greatest intensity for each MRM transition was applied
to the final method. This detection-method was used to screen for metabolites
as described in section 3.4.3. The selected ions, MRM transitions, and CEs are
shown and discussed in table 4.1, 4.2 and 4.3 in chapter 4.
3.4 Metabolite synthesis by human liver micro-
somes
The assay used in this study, is consolidated on former studies13;29 using micro-
somes as an in vitro synthesizing technique. Only small adjustments was done in
comparison to the study by Kuuranne et al.29. The full procedure is presented in
the following section.
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3.4.1 Enzymes, substrate and working solutions
Madol, enzymes and co-substrates were obtained, while metandieon, its metabo-
lites, methylnandrolone and ingredients for the buffer solutions were reagents
mostly existing at the Norwegian Doping Control Laboratory. Microsomal and
S9 fraction from human liver were purchased from BD biosolutions, and stored
at -80◦C. BD enzymes are two pooled mixtures of liver preparations from 150
different individual donors, to account for inter-individual variation2. Three co
factors were purchased from Sigma: nicotinamide adenine dinucleotide phosphate
(NADPH), uridine-5’-diphosglucuronic acid (UDPGA), and 3’-Phosphoadenosine-
5’-phosphosulfate (PAPS). D-saccharic acid 1,4-lactone (SL) was purchased from
Sigma. Buffer and working solutions were made as described in appendix and ,
and were placed on ice prior to the experiment.
3.4.2 In vitro assay
The In vitro enzyme assay, simulating the liver metabolism, was incubated to a
total volume of 100 µl, and distributed as shown following.
The standard assay The substrates was mixed according to table 3.1 and 3.2.
10 µl steroid working solution (substrate) was added into separate eppendorf tubes.
Blank samples were supplemented with 10 µl DMSO (solvent in the substrate
working solutions). 50 µl incubation solution was added to each sample (60 or 70
µl for samples with only one, or without enzymes). 10 µl of solely microsomes, or
10 µl of both enzymatic preparations (HLM and S9) were added to the samples
according to tables 3.1 and 3.2, and mixed carefully.
Incubation procedure Initiation of the reactions was done by adding 10 µl of
both NADPH and SL to all samples. The solutions were placed in a Thermomixer
Comfort (Eppendorf) at 37 ◦C, mixing (1000 rpm) for 4 hours in the standard
assay, and as given in table 3.3 and 3.4 for the time and enzyme dependent assay.
The cofactor solutions for the S9 incubated samples were prepared as described
in appendix , 15 minutes prior to phase II initiation. Samples with microsomes or
without enzymes were terminated after phase I reactions. Termination was done
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Table 3.1: The sample setup of the MD metabolism study. Components
mixed in the standard assay for generation of MD metabolites with HLM and S9.
Each substrate was incubated in three ways: with no enzymes, with microsomes
(HLM), or with both microsomes and S9 fraction from human liver.
Substrate Enzyme(s)
Blank HLM and S9
Metandienon No
HLM
HLM and S9
Epimetandienon No
HLM
HLM and S9
17,17-dimethyl metabolite No
HLM
HLM and S9
Substrate mix No
Table 3.2: The sample setup of the methylnortestosterone (MeNT) and madol
incubations. The components were mixed in the standard assay for generation
of their metabolites with HLM and S9. Each substrate was incubated in three
ways, as for MD.
Substrate Enzyme(s)
Blank HLM and S9
Methylnortestosterone No
HLM
HLM and S9
Madol No
HLM
HLM and S9
Substrate mix No
by adding 100 µl ice cold acetonitrile (ACN), vortexing, and placing on ice for 10
minutes.
Initiation of phase II reactions was achieved in the remaining samples by adding
10 µl of both UDPGA and PAPS. The samples were carefully vortexed, and placed
in the thermo mixer at 37 ◦C for 18 hours in the standard assay, and as given in
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the tables for the time and enzyme dependent assay. Termination was done with
ACN as described above.
The time and enzyme dependent assay Time of incubation in the two
phases was altered according to table 3.3 and 3.4.
Table 3.3: Time of incubation with microsomes or S9 fraction as the source
of enzymes in the in vitro synthesis of MD metabolites. The substrates were
incubated with either of the two enzyme sources (HLM or S9), and for four
different points of time. A blank sample was incubated with both enzymes, but
without a substrate.
Substrate Time of incubation with HLM Time of incubation with S9
Blank 24 19
Substrate mix 24 19
MD 2 4
4 15
6 17
24 19
EpiMD 2 4
4 15
6 17
24 19
Epimetendiol 2 4
4 15
6 17
24 19
17,17-dimethyl 2 4
metabolite 4 15
6 17
24 19
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Table 3.4: Samples with varying time of incubation with HLM and S9, in the
in vitro synthesis of MeNT metabolites.
Substrate Time of incubation with HLM Time of incubation with S9
Blank 20
MeNT 1 4
2 16
4 18
18 20
Isolation After termination, the sample solutions were centrifuged (Heraeus
Pico 17, Thermo) with 10000 rpm for 10 minutes. Samples supernatant were
transferred to clean glass test tubes, and the solvent was evaporated at 45-55 ◦C
under a stream of N2. 10 µl ISTD and 200 µl phosphate buffer were added to each
tube.
Enzymatic hydrolysis 100 µl β-glucuronidase was added to samples trans-
formed by phase II reactions. The samples were set at 50-55 ◦C for one hour for
enzymatic cleavage of bonds to glucuronic acid. 0,2 ml 3M Tris-buffer was added
to each sample after cooling down.
Extraction and derivatization All samples were extracted with 2 ml TBME.
They were vortexed for 3 minutes each, followed by centrifugation (Hettic Rotixa
50 RS) in 10 minutes at 1500 rpm. Sample separation was performed with a
freeze-bath of ethanol and dry-ice. The organic layer was transferred to clean 10
ml test tubes.
The solvent was evaporated on heat block (45-55 ◦C) under a stream of N2. The
inside of the tubes were poured with 0.2 ml ethanol. The ethanol was then evap-
orated to complete dryness of the sample, on heat block under a stream of N2.
All samples were derivatized with 40 µl MSTFA mix, and left on heat block (65-
75 ◦C) for approximately one hour. The solutions were thereafter transferred to
autosampler vials with inserts, and applied to GC-MS/MS for analysis.
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3.4.3 GC-MS(/MS) analysis of metabolites
The instrument and instrument conditions were identical as when establishing
the detection-method. The optimized detection-method with MRM transitions
described in section 3.1 was used to detect metabolites. Data processing from the
results of the synthesized metabolites, was carried out with ”Agilent Masshunter
Data Analysis and Reporting”.
3.5 Urine sample analysis
One sample that during recent doping control tested positive for MD was screened
by the method developed in section 3.1. The sample was already processed (hy-
drolyzed and derivatized), therefore no further processing was required. Vials with
the samples were applied to the GC-MS/MS, and run with MD detection-method.
Urine samples from a MeNT excretion study performed in Kreischa, Germany, by
Chundela and Große7, had been given to the Norwegian Laboratory of Doping
Analysis as a gift. The dispatch contained three urine samples collected prior,
and after a short and long period of time after MeNT administration to a male
volunteer. Processing of these urine samples followed the same procedure as for
the incubated samples, with a few exceptions. A double set of samples was carried
out, with one set of three samples going through the enzymatic hydrolysis. A
second set remained in free fraction. Extraction was performed with 5 ml of
TMBE. The rest of the preparation was in accordance with that described for
the incubated samples. Vials with samples were applied to the GC-MS/MS with
MeNT detection-method.
Chapter 4
Results and discussion
In this chapter, the results from this thesis, although closely related, are put in
three sections according to their origin. Firstly the results used in establishing the
detection-method, are briefly described. Then the results from the in vitro synthe-
sis of metabolites is presented. Last, results of further method- and incubation-
optimization are presented and discussed.
Metabolites produced in the in vitro synthesis of all three steroids, were recognized
with the developed detection-method. The time of incubation was adjusted, and
specific cofactors (NADPH, PAPS, UDPGA) were selected. This made it possible
to differ, and briefly examine, the enzymatic reactions.
4.1 Establishing the detection-method
An optimized instrumental method is necessary for detection of metabolites. The
procedure for establishing such a method, was described in section 2.7. Results
from establishing the detection-method for one metabolite per steroid are pre-
sented next. The approach of detecting metabolites through the distinct retention
time (RT) and by multiple reaction monitoring (MRM), applied to all metabolites
originating from every parent compound. A flow chart describing the route of
which the results were utilized in establishing the detection-method, is shown in
figure 4.1.
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Figure 4.1: Flow chart describing how results of the in vitro synthesis, or ac-
cessible reference compounds were utilized in establishing the detection-method.
The retention time and MRM transitions were combined into a selective and
sensitive detection-method.
4.1.1 Metandienon
All the MD metabolites in this study are commercially available. This makes es-
tablishing a detection-method easily feasible. Modification of the existing method
(from the pre-project), made detecting of the 17,17-dimethyl metabolite possible.
Retention time Isolation of the 17,17-dimethyl metabolite by gas chromato-
graphic separation, resulted in a peak at a distinct retention time (RT). RT of the
metabolite was 8.1 minutes (figure 4.2). RT is an instrument specific response, and
vary with column and chromatographic conditions (pressure, temperature etc.).
The derivatized 17,17-dimethyl metabolite, being a mono-TMS, had the lowest
mass among the examined MD metabolites. An increase in mass, will often give
an increase in boiling point. A reduced boiling point favors faster passage in
the type of column used in this study. On the basis of this, the 17,17-dimethyl
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Figure 4.2: Chromatogram of metandienon 17,17-dimethyl metabolite. 8.1
minutes is observed as the retention time for this metabolite from the reference
sample. A major peak is also seen at 15,2 minutes, which corresponds to the
internal standard (ISTD), methyltestosterone.
metabolite was expected to have an earlier RT than the other MD metabolites.
The RT of 8.1 minutes was implemented into the existing detection-method.
The mass spectrum An EI mass spectrum of a compound can be found from
a full-scan (m/z 50-550) of the entire sample at a distinct RT. The mass spectrum
of the 17,17-dimethyl metabolite (mono-TMS) at 8.1 minutes, is depicted in figure
4.3. A fragment of m/z 354 is consistent with the molecular weight (mono-TMS)
of the 17,17-dimethyl metabolite, and are abundant in the spectrum.
Figure 4.3: EI mass spectrum at 8.1 minutes, of the 17,17-dimethyl metabo-
lite (mono-TMS). The ions m/z 339 and 354 were selected as candidates for
precursor ions.
In selecting precursor ions from the spectrum, emphasis was aimed at fragments
of considerable signal intensities. This usually increases the specificity. Based on
the mass spectrum of 17,17-dimethyl metabolite, m/z 339 and 354 were selected
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as candidates for precursor ions. Mass spectra of the other MD metabolites are
not presented in this study, as they were presented in the pre-project.
Product ion mass spectra Upon the second fragmentation, the product ion
mass spectra were generated. The trimethylsilylated 17,17-dimethyl metabolite
had rich EI product ion mass spectra (figure 4.4).
(a)
(b)
Figure 4.4: Product ion mass spectra at 8.1 minutes of the 17,17-dimethyl
metabolite: a) precursor ion m/z 354, b) precursor ion m/z 339. Ions m/z 339,
148, 133 in a), and m/z 193 in b), were selected as potential product ions for
MRM transitions.
Lower masses precursor ions (m/z<100) does often result in less specific fragments
during product ion formation. The steroid nuclei resemblance among AAS gives
reason to believe that several lower masses precursor/product ions are mutual for
many AASs. Unique ions from the spectra, provides a strong detection-method.
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According to this, product ions were selected: m/z 193 from precursor ion m/z
339, and m/z 339, 148 and 133 from precursor ion m/z 354.
A similar approach was applied to the other MD metabolites during the pre-
project, thus will not be presented here.
Multiple reaction monitoring A precursor-product ion may function as a
characteristic transition (MRM), as explained during theory chapter. Based on
the mass spectra, four MRM transitions were suggested for confirmation of the
17,17-dimethyl metabolite. Abundance ratios of the MRMs were part of the iden-
tification criteria together with RT.
A positive result (detection) of the 17,17-dimethyl metabolite reference standard
was observed in the MRM chromatogram (figure 4.5). The MRM chromatogram
pictures the chromatographic and mass spectrometric data in a combined peak.
The detection-method turned out to be specific and sensitive. Other ion-pairs of
the 17,17-dimethyl metabolite may also function as MRM transitions, but this was
not further investigated here.
Figure 4.5: The MRM chromatogram of the 17,17-dimethyl metabolite. The
peaks indicate the abundance of each transition at that RT. The color of the
curve corresponds to a transition. Black = 339→ 193, blue = 354→ 133, green
= 354 → 148, and red = 354 → 339. The ratio percentage score above the
chromatogram indicate the match relative to the ratio observed in a reference.
The collision energy (CE) was ramped from 5 to 25 eV to obtain maximum sen-
sitivity and selectivity of the MRM transitions. Results of the ramped CE on
abundance of the MRM transitions of the 17,17-dimethyl metabolite can be found
in appendix , but the optimal values are presented next.
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The chromatographic and mass spectrometric results from establishing the
detection-method for MD and its metabolites, are reported in table 4.1.
Table 4.1: Chromatographic and mass spectrometric data for TMS-derivatives
of MD and its metabolites.
Component Retention Precursor Product CE (eV) Ratio
time (min) ion (MW) ion (MW)
Metandienon 15.1 444 206 15
(MD) 339 15 30.2
339 283 10 20.0
229 15 9.7
EpiMD 13.4 444 206 15
339 15 42.4
339 283 15 50.0
229 15 22,2
6β-hydroxyMD 16.2 517 229 25
337 15 9.0
429 20 11.0
Epimetendiol 9.6 358 301 15
343 15 50.0
448 358 5 5.5
194 10 2.5
17β-hydroxymethyl 13.4 339 193 15
metabolite 442 339 10 26.5
236 10 17.0
133 25 34.0
5β-THMT 12.8 270 255 10
213 10 75.2
435 345 5 100.0
255 15 36.3
17,17-dimethyl 8.1 339 193 15
metabolite 354 339 10 45.0
148 10 30.0
133 25 75.0
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4.1.2 Methylnortestosterone
It is desirable to include MeNT metabolites in the screening at the laboratory
to detect possible MeNT misuse. Metabolites of MeNT are not commercially
available. Thus, a modified approach was utilized in establishing the detection
method. Establishing the detection-method was performed based on the in vitro
synthesized samples. One of the observed metabolites is presented here as an
illustration of how these results contributed in establishing the detection-method.
This applied to all the metabolites, but full results on metabolites from the in
vitro synthesis, are given later, in section 4.2.
The mass spectrum The EI mass spectrum of the trimethylsilylated MeNT
metabolite M1 is displayed in figure 4.6. Spectra of the ”design steroid” metabo-
lites were captured from a GC-MS single quadropole, as this instrument proved
more sensitive than the GC-MS/MS was in full-scan mode.
Figure 4.6: Mass spectrum (GC-EI-MS) of MeNT M1 at 10.5 minutes, dis-
playing the possible molecular ion m/z 436. The ions m/z 421 and 256 were
selected as candidates for precursor ions.
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The initial focus when establishing the detection-method, was the search for TMS
derivatives of [MW]+ and [MW-15]+. The mass-to-change ratio of a probable
[MW]+ (m/z 436) show an increase of 4 units compared to MeNT. Structural
assignment of MeNT M1 was rendered from the this GC-MS scan, but is outlined
later together with discussions regarding dissociation pathway and characteristic
fragments (section 4.2). Based on the mass spectrum results, m/z 421 and 256
were selected as candidates for precursor ions.
Product ion mass spectra Product ion mass spectra of precursor ions m/z
421 and m/z 256, are depicted in figure 4.7. Product ions of substantial signal
intensity were in accordance with those presented in an unpublished study7.
(a)
(b)
Figure 4.7: Product ion mass spectra of precursor ions: a) m/z 421 and b)
m/z 256. The ions m/z 241 from m/z 421, and m/z 199 and 213 from m/z 256,
were selected as candidates for MRM transitions.
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Product ions of m/z 241 from precursor ion m/z 421, and m/z 199 and 213 from
precursor ion m/z 256 were selected as candidates for MRM transitions.
Retention time Since few publications have reported about MeNT metabolites,
neither published their RT, the RT was discovered by chromatographic interpre-
tations of the MRM transitions. The MRM transitions (presented in the next
paragraph) were captured from the above described mass spectra, and a poster of
an unpublished excretion study on MeNT7.
Figure 4.8: Chromatograms of selected MRM pairs of MeNT M1. Compared
with the chromatogram of a non-incubated sample and a MeNT reference stan-
dard, RT of 10.5 and 11.7 may indicate MeNT M1. Upper panel show m/z 421
→ 241, mid panel show m/z 256 → 199, and lower panel show m/z 256 → 213.
All these were MRM transitions comprised for confirmation of MeNT M1 in the
detection-method.
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The peaks at 10.5 and 11.7 minutes in the chromatograph in figure 4.8 comprises
all the MRM transitions selected for MeNT M1. This may indicate that MeNT
M1 has an epimeric compound eluting shortly after. This epimer (MeNT M2) is
described in section 4.2.
Multiple reaction monitoring By monitoring the response of the ion transi-
tions, a selective method for detection of MeNT is suggested. The chromatographic
and mass spectrometric results utilized in establishing the detection-method, are
summarized in table 4.2.
Table 4.2: Chromatographic and mass spectrometric results of MeNT and its
suggested metabolites.
Component Retention Precursor Product CE (eV) Ratio
time (min) ion (MW) ion (MW)
Methyl- 14.7 432 287 17
nortestosterone 285 15 20.0
300 15 14.0
MeNT 10.9 421 241 15
M1 256 199 8 23.1
213 12 3.6
MeNT 12.1 421 241 15
M2 256 143 8 62.0
213 12 35.7
MeNT 16.7 520 415 20
M3 287 17 20.5
194 30 10.2
MeNT 5.7 331 241 8
M4 143 35 2.1
256 143 20 1.0
4.1.3 Madol
Recent reports have described some madol metabolites44;18. Still, reference stan-
dards of the metabolites are not commercially available. A similar approach as
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for MeNT was employed in establishing the detection-method. Only one metabo-
lite is presented as illustration of establishing the detection-method of the madol
metabolites.
The mass spectrum EI mass spectrum of the trimethylsilylated possible madol
metabolite M1, is displayed in figure 4.9.
Figure 4.9: Mass spectrum (GC-EI-MS) at 15.0 minutes, possibly of madol
M1 metabolite.
The spectrum comprises both a possible [MW]+ of m/z 538, and the [MW-15]+ of
m/z 523 ions. This is considerably larger than madol, further described in section
4.2 Abundant signals were observed at m/z 523 and m/z 269, and selected as
candidates for further fragmentation.
Product ion mass spectra Product ion mass spectra of m/z 523 and m/z
269 (figure 4.10) displayed rich spectra with intense ions at m/z 343 and 253 for
precursor ion m/z 523, and m/z 213 and 159 for precursor ion m/z 269. Sobolevsky
et. al.45 used product ions m/z 343 and 253 from m/z 523, as sufficient recognition
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of madol M1. The same ions were chosen from these results. By extending the
method with two additional product ions, the intent was to enhance the selectivity.
(a)
(b)
Figure 4.10: Product ion mass spectra of precursor ion: a) m/z 523, and b)
m/z 269. Candidates for product ions for MRM transitions were m/z 253 and
343 from m/z 523, and m/z 213 and 159 from m/z 269.
Retention time A peak at 15.0 minutes in the chromatograph in figure 4.11
comprises all the MRM transitions selected for madol M1. Searching the liter-
ature was useful during this process, since some publications had reported mass
spectra of madol metabolites38;18;45. The MRM transitions was captured from
both the spectra after the in vitro synthesis, and from published spectra on madol
metabolites. A peak considerably smaller than at 15.0 minutes, but including all
the MRM transitions is observed at 16.2 minutes. This was not further examined
during this study.
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Figure 4.11: Chromatograms of suggested MRM pairs for the madol metabo-
lite. RT of 15.0 minutes may indicate madol M1, as it was common for all the
transitions, but nonexistent in the blank and substrate samples.
Multiple reaction monitoring The detection-method of madol M1 was estab-
lished by assembling the RT, MRM, CE and MRM ratios. The chromatographic
and mass spectrometric results of madol and its suggested metabolites are sum-
marized in table 4.3. Most MD and MeNT metabolites function well with a CE
of 15 eV, as seen in their detection-method. CE of 15 eV was therefore used in
the madol detection-method.
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Table 4.3: Chromatographic and mass spectrometric results of madol and
suggested metabolites.
Component Retention Precursor Product CE (eV) Ratio
time (min) ion (MW) ion (MW)
Madol 8.4 345 201 15
147 15 34.0
131 15 6.8
Madol 15.0 523 253 15
M1 343 15 30.0
269 213 15 51.8
159 15 39.5
Madol 14.1 446 431 15
M2 431 193 15 50.0
179 15 50.0
4.2 In vitro synthesized metabolites
The in vitro incubation successfully produced metabolites of both a familiar an-
abolic steroid and the ”designer steroids”. The AAS screening at the Norwegian
Doping Control Laboratory may incorporate MeNT and madol metabolites after
this thesis submission.
4.2.1 Metandienon
In vitro incubations of either MD, epiMD, or the 17,17-dimethyl metabolite gener-
ated four metabolites: 6β-hydroxy metandienon, epiMD, 17,17-dimethyl metabo-
lite, and the 17β-hydroxymethyl metabolite. Generation of epimetendiol or 5β-
THMT were nonexistent from these experiments, either did incubation with epime-
tendiol result in any metabolites.
6β-hydroxy metandienon
In vitro incubation of MD yielded 6β-hydroxy MD (figure 4.12), both in the pre-
project, and during this thesis. It stands to reason, since 6β-hydroxylation is
considered the main metabolic route in MD metabolism12. As 6β-hydroxy MD was
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generated in the pre-project, and has been reported in several excretion studies,
it is reasonable to believe that such hydroxylation is an uncomplicated metabolic
pathway during MD metabolism.
(a) (b)
(c) (d)
Figure 4.12: The MRM chromatogram verifying/refuting the existence of 6β-
metandienon in: a reference standard solution a), a matrix sample (HLM, S9
and co-factors) b), the in vitro incubated sample c), urine that tested positive
for metandienon usage by regular doping screening d).
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Epimetandienon
In contrast to the pre-project, where no epimerization was seen, epiMD was syn-
thesized in vitro from MD (figure 4.13) in this thesis. An effect presumably caused
by an increased availability of SULT43. This is reasonable as the concentration of
PAPS was increased (compared to the pre-project) in the incubation assay. A hy-
pothesis supported by earlier studies using microsomes. For instance Kuuranne et
al.29, whom stated that a low PAPS concentration probably was a limiting factor
for the yield of their metabolites.
(a) (b)
(c) (d)
Figure 4.13: The MRM chromatogram verifying/refuting the existence of
epimetandienon in: a reference solution a), a matrix sample (HLM, S9 and
co-factors) b), the in vitro incubated sample c), urine that tested positive for
metandienon use in regular doping screening d).
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17,17-dimethyl metabolite
In vitro generation of the 17,17-dimethyl metabolite from MD has been argued as
demanding in preceding reports58. Here, the 17,17-dimethyl metabolite was syn-
thesized in vitro, from either MD, or epiMD (figure 4.14). This implies that epiMD
is a precursor in the generation of the 17,17-dimethyl metabolite. Thus, micro-
somes with additives (co-factors) seem to comprise enzymes and factors necessary
for this conversion.
(a) (b)
(c) (d)
Figure 4.14: The MRM chromatogram verifying/refuting the existence of the
17,17-dimethyl metabolite in: a reference solution a), a matrix sample (HLM,
S9 and co-factors) b), the in vitro incubated sample c), urine that tested positive
for metandienon use in regular doping screening d).
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17β-hydroxymethyl metabolite
Zo¨llner et al.58, used the 17,17-dimethyl metabolite to produce the 17β-
hydroxymethyl metabolite. By doing so, they avoided the demanding conversion
of MD to the 17,17-dimethyl metabolite, and were able to examine the enzymatic
reactions behind. In this study, 17β-hydroxymethyl metabolite was also synthe-
sized in vitro from the 17,17-dimethyl metabolite (figure 4.15), but not from MD.
Referring to the above paragraph (17,17-dimethyl metabolite), generation of 17β-
hydroxymethyl metabolite should be feasible from MD at optimal incubation con-
ditions. It is of interest to be capable of synthesizing this metabolite. Reference
material of this metabolite is not commercially available, but if embedded in the
screening, the time window of detection of MD is increased41.
(a) (b)
(c) (d)
Figure 4.15: The MRM chromatogram verifying/refuting the existence of the
17β-hydroxymethyl metabolite in: a sample of the 17α-hydroxymethyl metabo-
lite reference (used to establish the MRMs, with only a deviating RT) a), a
matrix sample (HLM, S9 and co-factors) b), the in vitro incubated sample c),
urine that tested positive for metandienon usage in regular doping screening d).
In spite of irregularities of the ratio, are both sample c) and d) considered as
positive results
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4.2.2 Methylnortestosterone
Three metabolites of methylnortestosterone (MeNT) were observed after the in
vitro incubations. Detection and structural assignment of a metabolite is demand-
ing. The in vitro synthesized metabolites should share a similar core-structure as
the parent compound and other steroids, and thus hold EI fragmentation similar-
ities with previously characterized steroid and steroid metabolites. Effort during
this study, was therefore invested in searching through mass spectra of the incu-
bated samples, looking for characteristic ions for establishing a method, alongside
detecting likely metabolites and assigning their structure.
The epimeric metabolites
The first two observed metabolites, MeNT M1 and M2, had almost similar mass
spectra and MRM transitions, but differed in their RT. This is typical for epimeric
compounds43, as their conformation will retain them different through the column
of the gas chromatographic separation.
Molecular structure of MeNT M1 and M2 A part of the molecu-
lar structure (A- and B-ring) of MeNT is identical to among others: nan-
drolone, norethandrolone, norbolethone and mibolerone. Former studies on their
metabolism have revealed typical metabolic patterns. Scha¨nzer39 reviewed those
studies in 1996, and based on this information, a 5-α/β-reduction, followed by
reduction of the 3-keto group, seems likely for MeNT. It is emphasized that vari-
ations in the D-ring structure can influence the reductase activity. Regardless of
this, A-ring reduced metabolites would be expected for MeNT.
A structural assignment can be facilitated based on spectral interpretations20;16;21.
The mass spectrum of MeNT M1 was presented when establishing the detection-
method, figure 4.6. The mass spectrum of MeNT M2 at 12.1 minutes is quite
similar, and depicted in figure 4.16. In both scans, several mutual characteristics
are prominent. The EI fragmentation of these metabolites seem to generate an
ion of considerable intensity at m/z 143, and abundant fragments at m/z 436, 421,
256, and 130.
The per-TMS derivative of MeNT has a molecular weight of 432. An ion of four
mass equivalents more is visible in the metabolite spectrum. The m/z 436 fragment
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Figure 4.16: Mass spectrum (GC-EI-MS) at 12.1 minutes, possibly of MeNT
M2.
is possibly the intact trimethylsilylated M1/M2 ion, and the low abundance is
supported in an unpublished poster7. A gain of 4 Da may indicate a reduction
of double bonds in the parent compound, leading to four additional H-atoms. A
reduction of double bonds in MeNT, is only possible in the A- and/or B-ring. Ions
at m/z 421, are probably [MW-15]+, resulting from the loss of a methyl group.
[MW-15]+ has been used as a diagnostic characteristic16, but does not reveal much
structural information.
Figure 4.17: The molecular structure of the characteristic m/z 143 and 130
fragments, indicative of a 17α-alkylated steroid structure.
Chapter 4. Results and discussion 50
Ion at m/z 143 is due to fission of bonds in the D-ring of 17-methyl steroids (figure
4.17)16;48, and is often abundant together with m/z 130. Their abundance in the
EI mass spectra (figure 4.6 and 4.16) fortify the assumption that MeNT kept the
17α-alkylated structure intact during the metabolic reactions.
The C-19 methyl group has a remarkable effect on the fragmentation pattern16.
Norethandrolon is a 19-nor steroid with a similar A and B ring structure as MeNT.
In the mass spectra of norethandrolone 5α/β reduced metabolites are m/z 129
fragment abundant.
Figure 4.18: The molecular structure of the characteristic m/z 129 ion, prov-
ing the resemblance in the A-ring of MeNT M1/M2 and 5α/β-reduced metabo-
lites of norethandrolone.
This ion is deemed to consist of A-ring carbons according to Fragkaki et al.16.
The m/z 129 (figure 4.18) is abundant in the mass spectra of the first MeNT
metabolites, although difficult to spot compared to m/z 130 and 143, providing
considerable intensity. Due to all these mass spectrometric features, 17α-methyl-
5α/β-estrane-3α,17β-diols (figure 4.19) are proposed as structures of the epimeric
MeNT metabolites.
NMR is more reliable as a method of structure determination. Neither the referred
poster, nor this study, used NMR to confirm the metabolites. This might be an
idea for further studies for determining the MeNT M1/M2 structure.
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Figure 4.19: Suggested molecular structures of MeNT M1 and M2.
The verification of MeNT M1 and M2 Incubation of MeNT yielded 17α-
methyl-5α/β-estrane-3α,17β-diols (5α/β-estrane-diol metabolites) during this the-
sis. A positive result for the 5α/β-estrane-diols are depicted in figure 4.20 and 4.21.
In figure 4.20, the matrix sample (HLM, S9 and co-factors) responded to the MRM
transitions at 10.9 minutes. The only evidence of nonexistent MeNT M1 in this
sample is the deviant MRM ratio.
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(a) (b)
(c) (d)
Figure 4.20: The MRM chromatogram verifying/refuting the existence of the
5α-estrane-diol metabolite in: a sample of nonincubated MeNT a), a matrix
sample (HLM, S9 and co-factors) b), the in vitro incubated sample c), urine
from a MeNT excretion study d). The deviant MRM ratio of b) is amplified by
the colored area. This is an interference possibly caused by matrix compounds
responding to the selected transitions.
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(a) (b)
(c) (d)
Figure 4.21: The MRM chromatogram verifying/refuting the existence of the
5β-estrane-diol metabolite in: a sample of nonincubated MeNT a), a matrix
sample (HLM, S9 and co-factors) b), the in vitro incubated sample c), urine
from a MeNT excretion study d).
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The hydroxylated metabolite MeNT M3
One hydroxylated metabolite was recognized after incubation of MeNT. The un-
derstanding for such statement is described next.
Molecular structure of MeNT M3 EI mass spectrum of a possible third
MeNT metabolite (M3) is depicted in figure 4.22.
Figure 4.22: Mass spectrum (GC-EI-MS) at 16.7 minutes, possibly of MeNT
M3.
The EI mass spectrum display molecular ions at m/z 520, 430, 415, 287 and 194.
Compared to MeNT, m/z 520 is consistent with an additional TMS-group, and
a loss of a proton. This might indicate hydroxylated MeNT as a metabolite.
Ions m/z 287 and 194 shows structural resemblance with the mass spectrum of
MeNT. The presence of m/z 194 are of structural interest. It is considered typical
for the nandrolone A-ring, where it indicates a 3-keto-4-ene structure of 19-nor
steroids16;48 (figure 4.23).
The characteristic m/z 143 is not appearent in figure 4.22. An useful indication
that the D-ring structure has been subject to changes during the metabolism of
generating a third metabolite. Some D-ring alteration are comprehensive for the
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Figure 4.23: The molecular structure of the characteristic m/z 194 ion, illus-
trating the structural resemblance in the A- and B- ring of MeNT M3, with
that of MeNT and nandrolone before metabolism.
metabolism of 3-keto-4-ene steroids, mainly regarding the C-16, C-17 or C-18 posi-
tion15. 16-hydroxylation is a well-known metabolic pathway in familiar steroids40.
Fragmentation of a 16-hydroxylatet metabolite gives rise to characteristic frag-
ments of m/z 218 and 231 (figure 4.24).
Figure 4.24: Characteristic D-ring dissociation pathways, yielding ions of
m/z 218 and 231 upon fragmentation of trimethylsilylated 16,17-dihydroxy-17-
methyl steroids.
Based on these spectral interpretations, 16z,17β-dihydroxy-17α-methylestr-4-en-
3-one was put forward as the structure of MeNT M3 (figure 4.25).
Chapter 4. Results and discussion 56
Figure 4.25: The proposed structure of the third MeNT metabolite.
The verification of MeNT M3 Incubation of MeNT resulted in the generation
of 16z,17β-dihydroxy-17α-methylestr-4-en-3-one (16-hydroxy MeNT). Detection of
this metabolite post incubation, and in urine, are depicted in figure 4.26, together
with a sample of non-incubated MeNT .
(a) (b)
(c) (d)
Figure 4.26: The MRM chromatogram verifying/refuting the existence of the
16-hydroxy MeNT in: a sample of non-incubated MeNT a), a matrix sample
(HLM, S9 and co-factors) b), the in vitro incubated sample c), urine from a
MeNT excretion study d).
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Conjugation state When analyzing the urine samples, no MeNT metabolites
were found in the free fraction. After hydrolysis, all MeNT metabolites described
here, were detected. This is an indication that MeNT metabolites are excreted as
glucoronides (conjugates). The analogue 5α/β reduced nandrolone metabolites,
have all been determined as conjugates in preceding excretion studies42.
4.2.3 Madol
A recent study suggested MRMs of five potential metabolites45, while Gauthier
et al.18 suggested four metabolites, produced by human fresh hepatocytes. In
screening the in vitro incubated samples of madol for potential metabolites, one
metabolite was observed in this study. Since confirmatory synthesis was not per-
formed, the structure of the metabolites was not confirmed.
Molecular structure of madol M1 The EI mass spectrum of the possible
madol M1 was shown in figure 4.9. EI fragmentation of this metabolite seemed
to generate molecular ions of considerable intensity at m/z 523 and 146, and
abundant fragments at m/z 448, 394 and 269. The per-TMS derivative of madol
has the molecular weight of 360. An m/z 538 ion have additional 178 Da, which
corresponds to two additionally attached [TMSO]+ groups . This is probably the
intact trimethylsilyated madol M1 ion with additional diols. The dissociation is in
conformity with that of Gauthier et al.18. Ion m/z 523, is most likely [MW-CH3]
+.
A 17-methyl steroid structure is supported by the m/z 143 and 130 fragment16;48.
Abundant ions at m/z 129 are not solely connected to the A-ring, as described for
MeNT metabolites. A D-ring fragment of the same signal has been described for
17,19-dimethyl steroids48, as the C-19 methyl influences the fragment formation.
The m/z 117 and 147 ions have been seen in mass spectra of vicinal diols40. Vicinal
diols have previously been suggested and confirmed by NMR analysis, at position
C-2 and C-3 for madol M118. The structure in figure 4.27 result from the spectral
interpretations, and is consistent with former research on madol metabolites45;18;44.
Until recently, only A-ring alterations were confirmed for madol18. The 17α-
methyl, and the 17β-hydroxy group seemed to persist during metabolism, even
though metabolic action has been proposed in positions C-6, C-16 and C-1715. In
late 2012, urine from an excretion study was partly evaluated, and a 18-nor-17,17-
dimethyl and 2,3,16,17-tetrol structure were described45.
Chapter 4. Results and discussion 58
Figure 4.27: The proposed structure of madol M1, 17α-methyl-2β,3α,17β-
trihydroxy-5α-androstane (2,3,17-trihydroxy madol).
The verification of madol M1 2,3,17-trihydroxy madol was identified after in
vitro incubation of the parent compound, when screened through the established
detection-method (figure 4.28). This metabolite has a longer window for detection
than madol, and can be determined approximately one week post administration45.
Implementation of 2,3,17-trihydroxy madol in the AAS screening at the Norwegian
Doping Control Laboratory will better the detectability, as madol itself only is
detectable for 2 days44.
(a) (b)
Figure 4.28: The MRM chromatograms verifying/refuting the existence of
2,3,17-trihydroxy madol in: a sample of madol (not incubated) a), in vitro
incubated madol b).
Interestingly, the MRMs chosen in this study, proved more specific toward 2,3,17-
trihydroxy madol, than those reported by Sobolevsky et al.45. Only two transitions
per metabolite were implemented in their detection-method. For confirmation pur-
poses, WADA encourage more than two transitions52. By implementing additional
ion transitions, the specificity may increase. This might contribute to distinguish
between 2,3,17-trihydroxy madol and pregnanediol, mentioned to co-eluate with
2,3,17-trihydroxy madol45.
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Madol M2 A trace, possibly from a second metabolite, was observed, though
with a weak signal intensity. An EI mass spectrum at 14.1 minutes, of this sug-
gested metabolite, is depicted in figure 4.29.
Figure 4.29: Mass spectrum (GC-EI-MS), possibly of a second madol metabo-
lite.
It was not possible to verify the existence of a second madol metabolite in this
study. The MRM might not be correct or sensitive enough, or the microsomes
were unable to generate additional metabolite. By comparing the mass spectrum
to those reported by Gauthier et al.18, similarities were seen with the suggested
metabolite 17β-hydroxy-17α-methyl-5α-androstan-2-en-4-one.
4.3 Evaluation of the assay
The incubation conditions were evaluated with respect to time and to distinguish
the metabolic reactions. Some tendencies and assumptions might be drawn from
this evaluation. This section further address ways to optimize the incubation assay
in future studies.
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4.3.1 Metandienon
The optimal incubation time for generation of metabolites seemed to be diverse
between the metabolites. Welsch et al.56 suggested that a long incubation time
would reverse the metabolite synthesis, a phenomena observed in this study. The
optimal time of incubation was seen in the range of 2-24 hours, depending on the
metabolite and the responsible enzymes in question.
6β-hydroxy metandienon 6β-hydroxy MD was the only metabolite solely pro-
duced from MD with microsomes and NADPH. The in vitro assay provided both
CYPs (in microsomes) and necessary co-factors for hydroxylation. Thus removing
NADPH, and only incubating with S9, UDPGA and PAPS, gave no result of 6β-
hydroxy MD. The optimal time of incubation was 24 hours. This was the endpoint
in the experimental setup of the time-dependent assay. It is therefore unknown
whether 24 hours is the true optimal time, or if between 6 and 24, or after 24 hours
is optimal. It is reasonable that 6β-hydroxy MD was the only metabolite found
in the pre-project. Metabolites requiring only CYPs and NADPH were probably
the only operative reactions, and MD was the only incubated compound.
Epimetandienon Incubation of MD resulted in the formation of epiMD when
S9 and PAPS were available for the epimerization. By incubating in 15 hours,
the most adequate response was observed. It is noteworthy to implement that
already after 4 hours, epiMD had been generated. As no samples were gathered
between 4 and 15 hours, its optimum might be somewhere in between. Samples
incubated with microsomes and NADPH gave no epimerization. This indicates
that the sulphate conjugation is the reaction pathway of which the rearranged
epiMD is generated, as described by Scha¨nzer et al.43.
17,17-dimethyl metabolite Incubation of MD or epiMD with UDPGA and
co-factors generated the 17,17-dimethyl metabolite. The optimal incubation time
was 17 hours for MD, and 4 hours for epiMD. This logic relationship follows from
the above (epiMD) reasoning. EpiMD seem to be the intermediate between MD
and 17,17-dimethyl metabolite, and is necessary for the reaction of rearrangement
to occur. It seems to be a rapid but reversible reaction under the proper circum-
stances, due to the optimal time of incubation seen for epiMD. This metabolite
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was produced in all the incubations of both MD and epiMD, but was absent in
incubation solely comprising microsomes and NADPH.
17β-hydroxymethyl metabolite 17β-hydroxymethyl metabolite generated a
sufficient response in the detection-method after incubation of the 17,17-dimethyl
metabolite. The optimal incubation condition included two hours of incubation
with microsomes and NADPH. It remains a challenge to determine whether the re-
action is further optimized at an earlier point. The formation drop was remarkable
within 4 hours, suggesting a reversible reaction during microsome incubations.
4.3.2 Methylnortestosterone
The generated of all MeNT metabolites required microsomes and NADPH for their
formation in this study. The optimal time for maximal generation, varied from
1-18 hours. Even though microsomes and NADPH were required, glucuronidation
is probably true for all metabolites at the accessible cites provided during phase I
reactions. This is according to the lack of metabolites observed in the urine free
fraction.
5α-estrane-diol metabolite The maximum response of the 5α-estrane-diol
metabolite was observed after 1 hour of incubation. Whether the reaction is
optimal at an earlier point is unknown, the metabolite response dropped with a
factor of 3 within two hours of additional incubation. Reduction is a phase I reac-
tion that seems to proceed rapidly for MeNT, with available CYPs and NADPH
reducing equivalents.
5β-estrane-diol metabolite 5β-estrane-diol metabolite was not observed from
the optimization incubations. It was nevertheless generated during a 4 hour incu-
bation comprising S9 fraction and NADPH. This indicates that the two reduced
epimers follow different pathways in MeNT metabolism. This stands to reason
as the α- and β- reductase are individual enzymes located at different spots in
the hepatocytes. 5α reduced metabolites is usually more abundant than 5β. As
anticipated, neither of the reduced metabolites was generated from incubations
with S9, UDPGA and PAPS.
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16-hydroxy metabolite Microsome incubation of MeNT with NADPH re-
sulted in the 16-hydroxy metabolite. The time of incubation seemed to reach
an optimum at 18 hours, but traces were detected from 4 hours. It is unknown
whether the reaction is further optimal after 18 hours, as this was the final point
in the time dependent incubation assay. Hydroxylation is a CYP reaction, but
accordingly more demanding than the 4-5 reduction, judged upon these results.
4.3.3 Madol
No evaluation regarding time of incubation of madol was performed. This is sug-
gested in future work, and thus might reveal additional metabolites that faded out
with time spent in the standard incubation assay. The main metabolite of madol
was seen from incubation of microsomes with NADPH, suggesting encountering
parts of the phase I metabolism.
Chapter 5
Conclusion
The established detection-method of a distinct retention time and MRM transi-
tions of a steroid metabolite, was sufficient to detect: steroids and metabolites
in a reference mix, from in vitro synthesized samples, and from urine samples.
Microsomes showed promising as a technique to synthesize metabolites in vitro.
6β-hydroxyMD, epiMD and the 17,17-dimethyl metabolite was generated from in-
cubated MD. The last two was probably due to sufficient SULT availability. The
MD 17β-hydroxymethyl metabolite was generated from the 17,17-dimethyl MD
metabolite, and is of great interest since it is considered as a long term metabo-
lite of MD. Incubation of MeNT resulted in three metabolites: the 5α/β reduced
MeNT and a 16-hydroxy MeNT. A 2,3,17-trihydroxy madol was observed after in-
cubation of the parent steroid. The detection-method of MeNT and madol might
be implemented in the screening at the Norwegian Doping Control Laboratory
after this thesis submission. The optimal time of incubation varied among the
steroids. The most prominent enzymatic reactions seemed to be CYP mediated
reactions, but other reactions were observed as well. Future trials with microsomes
may focus on other AAS with unknown metabolic pathways, in order to identify
and incorporate new metabolites in the doping screening.
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Buffer solutions
Following appendix shows the buffer solutions used in the experimental assay.
All buffer solutions were made once, and kept in the refrigerator between experi-
ments.
Table 1: Buffer solutions for the experimental assay.
Buffer solution K2HPO4 KH2PO4 MgCl2 (in
phosphate buffer)
Molecular weight (g/mol) 174,1 136,1 95,2
Weight (g) 1,75 1,36 0,00475
Dissolvent (ml) 10,0 10,0 10,0
Concentration (M) 1.0 1,0 0,005
Phosphate buffer 0,005 M phosphate buffer was made by mixing 100 µl 1M
KH2PO4 and 400 µl 1M K2HPO4, and dilute with milli-Q water to a total volume
of 10 ml.
Incubation buffer Incubation buffer was made by mixing 4,8 mg of MgCl2, 400
µl 1M K2HPO4, and 100 µl 1M KH2PO4, and dilute with milli-Q water to a total
volume of 10 ml. The buffer solutions were placed in the refrigerator before and
between experiments.
i
Working solutions
Following appendix shows the working solutions used in the experimental assay.
Several synthesis were performed, all of which followed the experimental setup
described in section 3.4.2.
The substrate working solution (100µM) of each steroid was made once, by dis-
solving the amount (mg) shown in table 2 in equal volume (ml) of DMSO to a
concentration of 1.0 mg/ml. 150 µl 1 mg/ml solution was diluted with DMSO
to a total volume of 5 ml, making up the 0.1 M solution. Working solutions of
epiMD and epimetendiol were made from stock solutions ”in-house”. Since these
were 1 mg/ml in ethanol, 30 µl were evaporated under N2. 1 ml DMSO was added
to each dry sample, making up the 100 µM working solution. The solutions were
stored in a cold-storage chamber between experiments.
Table 2: Working solutions of the steroid substrates. All substrates were
dissolved in equal amount (ml) DMSO as weigth (mg) of substrate.
MW (g/mol) Weight (mg)
MD 300.4 0.81
17,17-dimethyl 285.4 0.84
metabolite
MeNT 288.4 1.41
Madol 288.5 1.40
NADPH (50mM) was made by mixing 10.0 (±0.2) mg NADPH with 240 µl in-
cubation buffer in an eppendorf tube, and vortexed carefully. SL (50mM) was
made by mixing 3.0 (±0.2) mg SL with 250 µl phosphate buffer in an eppendorf
tube, and vortexed carefully. The solutions were then placed on ice. Solution
of UDPGA and PAPS were prepared 15 minutes prior to incubation of phase II
reactions. 3.3 (±0.2) mg UDPGA was mixed with 100 µl incubation buffer in an
ii
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eppendorf tube. 0.25 (±0.1) mg PAPS was mixed with 1000 µl incubation buffer
in an eppendorf tube.
Chemicals and solutions
Chemicals and solutions (in appendix and ) used during this study are presented
below. All metabolites were pure (≥95%), and the solvents were of pro-analyse
quality:
MD, metabolites and ISTD:
MD = 17β-hydroxy-17α-methylandrosta-1,4-dien-3-one
17α-hydroxymethyl metabolite = 17α-hydroxymethyl-17α-methyl-18-norandrosta-
1,4,13-trien-3-one
EpiMD = 17α-hydroxy-17β-methylandrosta-1,4-dien-3-one
6β-hydroxyMD = 6β,17β-dihydroxy-17α-methylandrosta-1,4-dien-3-one
Epimetendiol = 17β-methyl-5β-androsta-1-ene-3α,17α-diol
5β-THMT = 17α-methyl-5β-androstane-3α,17α-diol
Madol = 17α-methyl-17β-hydroxy-5α-androst-2-ene
MeNT = 17β-hydroxy-17α-methylestr-4-en-3-one
Solvents:
Ethanol
Methanol
Milli-Q water
DMSO
Phosphate buffer
Incubation buffer
Tris-buffer
TBME
Other reagents:
iv
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Human liver microsomes
S9 fraction from human liver
SL
β-glucuronidase
ACN
MSTFA mix:
- MSTFA
- NH4
- EtSH
Heptan
Establishing the
detection-method
Full results of establishing the detection-method towards MeNT and Madol follows:
• The EI mass spectra of metabolites: MeNT and Madol (figure 1).
• Product ion mass spectra of selected precursor ions from the EI mass spectra:
MeNT with precursor ion m/z 432, and madol with precursor ion m/z 345
(figure 2).
• The intensity distribution after varying the CE MRM transition of 17,17-
dimethyl metabolite of MD is shown in figure 3.
Appendix vii
(a)
(b)
(c)
Figure 1: Mass spectra (GC-EI-MS) of: MeNT a), madol b). The madol
isomer, eluting shortly after madol (tail) is shown in c)
Appendix viii
(a)
(b)
Figure 2: Product ion mass spectra of precursor ions: m/z 432 of MeNT a),
m/z 345 of madol b).
Figure 3: The intensity distribution with different CE, for the MRMs of the
TMS-derivative of 17,17-dimethyl metabolite.
